FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
HALIFAX, NOVA SCOTIA — As Halifax confronts one of the most pressing housing shortages in…
PARIS, FRANCE — Servair, a member of gategroup, is once again reaching for the stars.…
Sale hailed as major sign of confidence in city’s real estate market and security in UAE …
By Daniel Welinder, Head of Aircraft Management and Sales at Jet Agent The acquisition of…
COPENHAGEN, DENMARK — DeCarbon Copenhagen 2026 will convene Europe’s biomass, carbon markets and digital infrastructure…
LONDON, UNITED KINGDOM — Parabellum Investments has announced the sale of business process outsourcing (BPO)…